中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.045 seconds)

    TREATMENT OF LAG-3 POSITIVE TUMORS
    2.
    发明申请
    TREATMENT OF LAG-3 POSITIVE TUMORS 有权

    公开(公告)号：US20210261666A1

    公开(公告)日：2021-08-26

    申请号：US16616574

    申请日：2018-05-30

    Applicant: Bristol-Myers Squibb Company

    Inventor： James NOVOTNY, JR. ,  Nils LONBERG ,  Cyrus HEDVAT ,  Raphael CLYNES ,  Darren LOCKE ,  John P. COGSWELL ,  Jeffrey JACKSON ,  Christopher HARBISON ,  Robin EDWARDS

    IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

    Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-Ll positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.

    OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
    8.
    发明申请
    OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF 审中-公开

    公开(公告)号：US20190256594A1

    公开(公告)日：2019-08-22

    申请号：US16288245

    申请日：2019-02-28

    Applicant: Bristol-Myers Squibb Company

    Inventor： Nils LONBERG ,  Mohan SRINIVASAN

    IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68

    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

Patent Agency Ranking